Cargando…
Reduced-fluence photodynamic therapy and anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy in an Indian population
AIMS: The aim was to study the efficacy of combined therapy with reduced-fluence photodynamic therapy (RFPDT) and intravitreal bevacizumab/ranibizumab from the Indian subcontinent. SETTINGS AND DESIGN: This was a single-center, retrospective interventional study. METHODS: Thirty-five eyes of 34 pati...
Autores principales: | Sen, Parveen, Bhende, Muna, Sachidanandam, Ramya, Bansal, Nishat, Sharma, Tarun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322706/ https://www.ncbi.nlm.nih.gov/pubmed/28112132 http://dx.doi.org/10.4103/0301-4738.198856 |
Ejemplares similares
-
Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
por: Bansal, Aditya, et al.
Publicado: (2017) -
Combined argon laser photocoagulation and antivascular endothelial growth factor for management of macular polypoidal choroidal vasculopathy
por: Sen, Parveen, et al.
Publicado: (2016) -
Incidence, outcomes, and risk factors for hemorrhagic complications in eyes with polypoidal choroidal vasculopathy following photodynamic therapy in Indian subjects
por: Rishi, Pukhraj, et al.
Publicado: (2017) -
Reply to comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
por: Bansal, Aditya, et al.
Publicado: (2018) -
Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy
por: Ngo, Wei Kiong, et al.
Publicado: (2020)